NL-OMON20310招募中不适用
engthening Adalimumab Dosing Interval in IBD patients in long term remission, theLADI study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Erasmus MC
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age 18 or older.
- •Written informed consent.
排除标准
- •Concomitant corticosteroid usage
- •Imminent need for IBD-related surgery
研究者
相似试验
尚未招募
4 期
engthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study.Inflammatory bowel disease10017969NL-OMON40962Erasmus MC, Universitair Medisch Centrum Rotterdam80
进行中（未招募）
不适用
Increasing the time between adalimumab injections from two to threeweeks, in patients with inflammatory bowel disease.Inflammatory bowel diseaseEUCTR2014-001919-39-NLErasmus MC
撤回
3 期
engthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study.10017969IBDNL-OMON40152Erasmus MC, Universitair Medisch Centrum Rotterdam72
招募中
4 期
engthening Adalimumab Dosing Interval in quiescent Crohn*s disease patients: the LADI study.Crohn's diseaseNL-OMON47881Radboud Universitair Medisch Centrum174
招募中
不适用
engthening Adalimumab Dosing Interval in quiescent Crohn’s disease patientsNL-OMON21837Radboud university medical center, PO box 9101, 6500 HB Nijmegen Geert-Grooteplein Zuid 10174